B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.

Arribas, I; Maluquer, C; Pomares, H; Carro, I; Baca, C; Bosch, A; Arévalo, C E; Montané, C; Ribes-Amorós, J; Zamora, L; Granada, I; Gamundi, E; Arnan, M; Sureda, A

Arribas, I; Maluquer, C; Pomares, H; Carro, I; Baca, C; Bosch, A; Arévalo, C E; Montané, C; Ribes-Amorós, J; Zamora, L; Granada, I; Gamundi, E; Arnan, M; Sureda, A.

Afiliação

Arribas I; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Maluquer C; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Pomares H; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Carro I; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Baca C; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Bosch A; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Arévalo CE; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Montané C; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Ribes-Amorós J; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Zamora L; Hematology Department, ICO-Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain.
Granada I; Hematology Department, ICO-Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain.
Gamundi E; Pathology Department, Bellvitge University Hospital, Barcelona, Spain.
Arnan M; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Sureda A; Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.

Leuk Lymphoma ; 64(10): 1701-1705, 2023 10.

Article em En | MEDLINE | ID: mdl-37455651

Assuntos

Leucemia-Linfoma Linfoblástico de Células Precursoras B; Humanos; Lenalidomida/efeitos adversos; Talidomida/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Leucemia Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google